F. Stephen Hodi

4 ta ish

Cornell University

1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

   F. Stephen Hodi, Steven O’Day, David F. McDermott +26

   MaqolaOAOchiq kirish201010 iqtibos

   ABIABI:AkademIndex/2026.other.121325

2. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

   Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer +27

   MaqolaOAOchiq kirish20123 iqtibos

   ABIABI:AkademIndex/2026.other.132162

3. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

   James Larkin, Vanna Chiarion‐Sileni, René González +28

   MaqolaOAOchiq kirish20153 iqtibos

   ABIABI:AkademIndex/2026.other.170114

4. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

   Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González +30

   MaqolaOAOchiq kirish20172 iqtibos

   ABIABI:AkademIndex/2026.other.082822